Literature DB >> 25232238

Factors affecting effectiveness of vaccination against hepatitis B virus in hemodialysis patients.

Theodoros Eleftheriadis1, Georgios Pissas1, Georgia Antoniadi1, Vassilios Liakopoulos1, Ioannis Stefanidis1.   

Abstract

Hepatitis B virus (HBV) is a major global health problem. Despite the success of the general measures against blood transmitted infections in hemodialysis (HD) units, the prevalence of HBV infection among the HD patients is still high. Thus vaccination against HBV is indicating in this population. However, compared with the general population the seroprotection achieved in HD patients remains relatively low, at about 70%. In this review patient, HD procedure and vaccine-associated factors that affect the efficacy of HBV vaccination are analyzed. Also alternative routes of HBV vaccine administration as well as new and more immunogenic vaccine formulations are discussed. However, besides scientific progress, vigilance of HD physicians and staff regarding the general measures against the transmission of blood borne infections and the vaccination against HBV is also required for reducing the prevalence of this viral infection.

Entities:  

Keywords:  Adjuvant; Hemodialysis; Hepatitis B virus epidemiology; Hepatitis B virus vaccine; Immunostimulant; Intradermal

Mesh：

Substances：

Year:  2014        PMID： 25232238      PMCID： PMC4161789          DOI： 10.3748/wjg.v20.i34.12018

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN： 1007-9327            Impact factor:   5.742


  91 in total

1.  Meta-analysis: the impact of diabetes mellitus on the immunological response to hepatitis B virus vaccine in dialysis patients.

Authors:  F Fabrizi; V Dixit; P Martin; P Messa
Journal:  Aliment Pharmacol Ther       Date:  2011-02-01       Impact factor: 8.171

2.  Host responses to hepatitis B infection in patients in a chronic hemodialysis unit.

Authors:  W T London; J S Drew; E D Lustbader; B G Werner; B S Blumberg
Journal:  Kidney Int       Date:  1977-07       Impact factor: 10.612

Review 3.  The perfect mix: recent progress in adjuvant research.

Authors:  Bruno Guy
Journal:  Nat Rev Microbiol       Date:  2007-07       Impact factor: 60.633

4.  Good response to HBsAg vaccine in dialysis patients is associated with high CD4+/CD8+ ratio.

Authors:  Funda Sari; Hulya Taskapan
Journal:  Int Urol Nephrol       Date:  2011-08-02       Impact factor: 2.370

Review 5.  Meta-analysis: the adjuvant role of granulocyte macrophage-colony stimulating factor on immunological response to hepatitis B virus vaccine in end-stage renal disease.

Authors:  F Fabrizi; S V Ganeshan; V Dixit; P Martin
Journal:  Aliment Pharmacol Ther       Date:  2006-09-01       Impact factor: 8.171

6.  Vaccine against human hepatitis B.

Authors:  E B Buynak; R R Roehm; A A Tytell; A U Bertland; G P Lampson; M R Hilleman
Journal:  JAMA       Date:  1976-06-28       Impact factor: 56.272

7.  Evolution of naturally acquired hepatitis B immunity in the long-term hemodialysis population.

Authors:  Andre F Charest; Anne Grand'Maison; James McDougall; Marc B Goldstein
Journal:  Am J Kidney Dis       Date:  2003-12       Impact factor: 8.860

8.  Rapid, enhanced, and persistent protection of patients with renal insufficiency by AS02(V)-adjuvanted hepatitis B vaccine.

Authors:  Murielle Surquin; Christian L Tielemans; Imre Kulcsár; Miroslav Ryba; Péter Vörös; Olivier Mat; Serge Treille; Michel Dhaene; Jean-Claude Stolear; Sherine O Kuriyakose; Maarten X Leyssen; Sophie A Houard
Journal:  Kidney Int       Date:  2009-11-25       Impact factor: 10.612

9.  Intravenous iron attenuates postvaccination anti-HBsAg titres after quadruple hepatitis B vaccination in dialysis patients with erythropoietin therapy.

Authors:  J-H Liu; Y-L Liu; H-H Lin; Y-F Yang; H-L Kuo; P-W Lin; C-C Huang
Journal:  Int J Clin Pract       Date:  2008-04-10       Impact factor: 2.503

Review 10.  Immune cell dysfunction and inflammation in end-stage renal disease.

Authors:  Michiel G H Betjes
Journal:  Nat Rev Nephrol       Date:  2013-03-19       Impact factor: 28.314
View more
  9 in total

1.  A randomized, controlled clinical trial to evaluate the immunogenicity of a PreS/S hepatitis B vaccine Sci-B-Vac™, as compared to Engerix B®, among vaccine naïve and vaccine non-responder dialysis patients.

Authors:  E Elhanan; M Boaz; I Schwartz; D Schwartz; G Chernin; H Soetendorp; A Gal Oz; A Agbaria; T Weinstein
Journal:  Clin Exp Nephrol       Date:  2017-04-29       Impact factor: 2.801

2.  Comparing Assay Performance of ELISA and Chemiluminescence Immunoassay in Detecting Antibodies to Hepatitis B Surface Antigen.

Authors:  Mridula Madiyal; Siddharth Sagar; Shashidhar Vishwanath; Barnini Banerjee; Vandana Kalwaje Eshwara; Kiran Chawla
Journal:  J Clin Diagn Res       Date:  2016-11-01

3.  Factors affecting responsiveness to hepatitis B immunization in dialysis patients.

Authors:  Ali Asan; Huriye Demirhan; Hülya Çetin Sorkun; Sevgi Özkan; Mehtap Aydın; Davut Akın; Bengü Tatar; Binali Çatak; Alper Şener; Şükran Köse
Journal:  Int Urol Nephrol       Date:  2017-06-15       Impact factor: 2.370

4.  Impaired Immune Response to SARS-CoV-2 Vaccination in Dialysis Patients and in Kidney Transplant Recipients.

Authors:  Thilo Kolb; Svenja Fischer; Lisa Müller; Nadine Lübke; Jonas Hillebrandt; Marcel Andrée; Michael Schmitz; Claudia Schmidt; Seher Küçükköylü; Lynn Koster; Margarethe Kittel; Lea Weiland; Karl W Dreyling; Gerd Hetzel; Ortwin Adams; Heiner Schaal; Katrin Ivens; Lars C Rump; Jörg Timm; Johannes Stegbauer
Journal:  Kidney360       Date:  2021-07-13

5.  Occult Hepatitis B Infection among Hemodialysis in Tabriz, Northwest of Iran: Prevalence and Mutations within the S Region.

Authors:  Narges Eslami; Vahdat Poortahmasebi; Javid Sadeghi; Reza Ghotaslou; Bahram Niknafs; Hossein Bannazadeh Baghi; Mahin Ahangar Oskouee
Journal:  Can J Infect Dis Med Microbiol       Date:  2022-06-28       Impact factor: 2.585

6.  Humoral Response after Three Doses of mRNA-1273 or BNT162b2 SARS-CoV-2 Vaccines in Hemodialysis Patients.

Authors:  José Jesús Broseta; Diana Rodríguez-Espinosa; Elena Cuadrado; Néstor Rodríguez; José Luis Bedini; Francisco Maduell
Journal:  Vaccines (Basel)       Date:  2022-03-27

7.  Antibody maintenance and breakthrough infections 6 months after complete COVID-19 vaccination with the mRNA-1273 and BNT162b2 vaccines in hemodialysis patients.

Authors:  Diana Rodríguez-Espinosa; José Jesús Broseta; José Luis Bedini; Néstor Rodríguez; Francisco Maduell
Journal:  Clin Kidney J       Date:  2021-12-16

8.  The Guerilla Tactics of Hepatitis B Virus in Hemodialysis: Fighting a Stubborn Foe.

Authors:  Leslie P Wong
Journal:  Kidney Med       Date:  2019-10-30

9.  Humoral and Cellular Responses to mRNA-1273 and BNT162b2 SARS-CoV-2 Vaccines Administered to Hemodialysis Patients.

Authors:  José Jesús Broseta; Diana Rodríguez-Espinosa; Néstor Rodríguez; María Del Mar Mosquera; María Ángeles Marcos; Natalia Egri; Mariona Pascal; Erica Soruco; José Luis Bedini; Beatriu Bayés; Francisco Maduell
Journal:  Am J Kidney Dis       Date:  2021-06-24       Impact factor: 8.860
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.